News
ATXS
9.45
-6.34%
-0.64
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 21h ago
Astria Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Reiterates Buy on Astria Therapeutics, Maintains $16 Price Target
Benzinga · 1d ago
Promising Developments at Astria Therapeutics Bolster Buy Recommendation
TipRanks · 1d ago
Astria Therapeutics Is Maintained at Outperform by Oppenheimer
Dow Jones · 1d ago
Oppenheimer Maintains Outperform on Astria Therapeutics, Raises Price Target to $28
Benzinga · 1d ago
ASTRIA THERAPEUTICS <ATXS.O>: OPPENHEIMER RAISES TARGET PRICE TO $28 FROM $26
Reuters · 1d ago
Oppenheimer Remains a Buy on Astria Therapeutics (ATXS)
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Shattuck Labs (STTK) and Astria Therapeutics (ATXS)
TipRanks · 1d ago
Astria Therapeutics price target raised to $28 from $26 at Oppenheimer
TipRanks · 1d ago
TD Cowen Sticks to Its Buy Rating for Astria Therapeutics (ATXS)
TipRanks · 1d ago
Promising Outlook for Astria Therapeutics: Strong Financials and Key Program Advancements Support Buy Rating
TipRanks · 1d ago
U.S. RESEARCH ROUNDUP-Cisco, Freshpet, Nvidia
Reuters · 1d ago
Astria TherapeuticS GAAP EPS of -$0.42 in-line
Seeking Alpha · 1d ago
Based on the provided financial report, the title of the article is: "Form 10-Q for the quarterly period ended September 30, 2024
Press release · 1d ago
*Astria Expects Cash, Cash Equivalents and Short-Term Investments as of Sept 30 Sufficient to Fund Ops Into Mid-2027 >ATXS
Dow Jones · 1d ago
*Astria Therapeutics: Final 3- and 6-Mo Results From ALPHA-STAR Trial of Navenibart Expected in 4Q
Dow Jones · 1d ago
*Astria Therapeutics: Navenibart (STAR-0215) on Track for Expected Phase 3 Initiation in 1Q of 2025 >ATXS
Dow Jones · 1d ago
*Astria Therapeutics 3Q Loss $24.5M >ATXS
Dow Jones · 1d ago
*Astria Therapeutics: Phase 1a Trial of STAR-0310 in Healthy Subjects Expected to Initiate in Q1 2025 >ATXS
Dow Jones · 1d ago
More
Webull provides a variety of real-time ATXS stock news. You can receive the latest news about Astria Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ATXS
Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis (AD). The Company owns two patent families directed to STAR-0215. The first patent family is directed to the composition of matter of its product candidate STAR-0215 and its use in treating various plasma kallikrein associated disorders including HAE. In the second patent family, the Company owns one International (PCT) patent application directed to methods of treating various plasma-kallikrein associated disorders, including HAE, with specific dosing regimens of the STAR-0215 antibody.